{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Liu X"],"funding":["China Postdoctoral Science Foundation","Natural Science Foundation of Fujian Province (Fujian Provincial Natural Science Foundation)","National Natural Science Foundation of China (National Science Foundation of China)"],"pagination":["11187"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12711902"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(1)"],"pubmed_abstract":["The durability and protective effect of naturally acquired antibodies against hepatitis E virus (HEV) reinfection and clinical progression remain unclear in humans. In a 103-month longitudinal analysis of 7032 adult placebo recipients (aged 16 to 65 years) from a phase 3 HEV vaccine trial in China, we demonstrated that baseline anti-HEV IgG seropositivity (n = 3194) conferred over 50% higher protection against reinfection compared with seronegative individuals (n = 3838), with this protective effect remaining consistent over 8.5 years. A non-linear dose-response relationship was observed, whereby baseline anti-HEV IgG concentrations ≥0.25 WHO units/mL were associated with at least a 50% reduction in infection risk, with higher baseline antibody levels correlated with a lower risk of infection. Natural immunity provided approximately 70% protection against clinically apparent hepatitis E in the cohort, with 10 symptomatic cases identified over a decade of active surveillance. Six were hospitalized, all of whom were baseline seronegative. These findings establish that natural HEV immunity provides durable, though incomplete, protection."],"journal":["Nature communications"],"pubmed_title":["Long-term protection from naturally acquired immunity against hepatitis E virus reinfection."],"pmcid":["PMC12711902"],"funding_grant_id":["GZB20250195","2022J02005","32370160","823B2086"],"pubmed_authors":["Zheng Z","Chen Q","Zhang J","Zang X","Hu X","Jiang H","Yang C","Liu X","Huang S","Zhuang C","Zhu K","Huang X","Xia N","Zhu W","Wu T","Wang Y","Liu D","Su Y","Bi Z"],"additional_accession":[]},"is_claimable":false,"name":"Long-term protection from naturally acquired immunity against hepatitis E virus reinfection.","description":"The durability and protective effect of naturally acquired antibodies against hepatitis E virus (HEV) reinfection and clinical progression remain unclear in humans. In a 103-month longitudinal analysis of 7032 adult placebo recipients (aged 16 to 65 years) from a phase 3 HEV vaccine trial in China, we demonstrated that baseline anti-HEV IgG seropositivity (n = 3194) conferred over 50% higher protection against reinfection compared with seronegative individuals (n = 3838), with this protective effect remaining consistent over 8.5 years. A non-linear dose-response relationship was observed, whereby baseline anti-HEV IgG concentrations ≥0.25 WHO units/mL were associated with at least a 50% reduction in infection risk, with higher baseline antibody levels correlated with a lower risk of infection. Natural immunity provided approximately 70% protection against clinically apparent hepatitis E in the cohort, with 10 symptomatic cases identified over a decade of active surveillance. Six were hospitalized, all of whom were baseline seronegative. These findings establish that natural HEV immunity provides durable, though incomplete, protection.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-06T05:07:20.909Z","creation":"2026-05-26T03:12:07.653Z"},"accession":"S-EPMC12711902","cross_references":{"pubmed":["41407683"],"doi":["10.1038/s41467-025-66188-8"]}}